TRBC1 and peripheral T-cell lymphoma, not otherwise specified: In the dose-escalation part of the ongoing phase 1/2 LIBRA4 trial, patients with relapsed/refractory peripheral T cell lymphoma received T cell antigen receptor beta-chain constant domain 1 (TRBC1)-targeted chimeric antigen receptor T cell therapy, showing limited toxicity and encouraging preliminary clinical responses.